In vitro bacteriostatic effects of Polymyxin B combined with Propofol medium and long chain fat emulsion injection against Escherichia coli.

BACKGROUND Polymyxins is a class of cyclic polypeptide antibiotics with strong antibacterial activity against Gram-negative bacteria. However, bacteria become resistant to Polymyxins. Thus, Polymyxin B (PMB) in combination with other antimicrobials may be a better choice in clinic. This study aimed to evaluate the synergistic bacteriostatic effect of PMB combined with Propofol medium and long chain fat emulsion injection against Escherichia coli in vitro. METHODS The Minimal Inhibitory Concentration of Polymyxin B combined with Propofol medium and long chain fat emulsion injection and two drugs used alone against Escherichia coli were detected with the Kirby-Bauer disk diffusion (K-B) method, and the diameter of the inhibition zone was calculated to evaluate bacteriostatic effects. RESULTS Different concentrations of PMB all had obvious bacteriostatic effects on Escherichia coli, while different concentrations of Propofol medium and long chain fat emulsion injection had no bacteriostatic effects on Escherichia coli. The bacteriostatic effect of the combination of PMB with Propofol medium and long chain fat emulsion injection against Escherichia coli was synergistic, and no effects of uncorrelated and antagonism were observed in this combination. CONCLUSIONS PMB combined with Propofol medium and long chain fat emulsion injection can improve the bacteriostatic effect for Escherichia coli in vitro.

[1]  A. Qadri,et al.  Lysophosphatidylcholine Potentiates Antibacterial Activity of Polymyxin B , 2020, Antimicrobial Agents and Chemotherapy.

[2]  R. Salomão,et al.  Sepsis: evolving concepts and challenges , 2019, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[3]  W. Hazzah,et al.  Evaluation of antibiotic susceptibility test results: how guilty a laboratory could be? , 2019, Journal of the Egyptian Public Health Association.

[4]  F. Rabanal,et al.  Recent advances and perspectives in the design and development of polymyxins. , 2017, Natural product reports.

[5]  A. Tamhankar,et al.  The distribution of carbapenem‐ and colistin‐resistance in Gram‐negative bacteria from the Tamil Nadu region in India , 2017, Journal of medical microbiology.

[6]  H. Boucher,et al.  Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications , 2017, Pharmacotherapy.

[7]  K. Gothandam,et al.  Characterization of carbapenem-resistant Gram-negative bacteria from Tamil Nadu , 2016, Journal of chemotherapy.

[8]  J. Li,et al.  Polymyxins: a new hope in combating Gram-negative superbugs? , 2016, Future medicinal chemistry.

[9]  R. Pearce,et al.  Lipid-free Fluoropolymer-based Propofol Emulsions and Lipid Reversal of Propofol Anesthesia in Rats , 2016, Anesthesiology.

[10]  S Gnanakaran,et al.  Permeability Barrier of Gram-Negative Cell Envelopes and Approaches To Bypass It. , 2015, ACS infectious diseases.

[11]  K. Yu,et al.  Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009. , 2015, Diagnostic microbiology and infectious disease.

[12]  S. Vasoo,et al.  Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. , 2015, Mayo Clinic proceedings.

[13]  J. Bultinck,et al.  Nitric oxide production by endotoxin preparations in TLR4-deficient mice. , 2014, Nitric oxide : biology and chemistry.

[14]  D. Nicolau,et al.  In Vitro Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii , 2013, Antimicrobial Agents and Chemotherapy.

[15]  C. Clancy,et al.  The Combination of Doripenem and Colistin Is Bactericidal and Synergistic against Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae , 2012, Antimicrobial Agents and Chemotherapy.

[16]  T. Tan,et al.  Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B , 2011, PloS one.

[17]  Jian Li,et al.  Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. , 2007, The Journal of antimicrobial chemotherapy.

[18]  E. Groisman,et al.  Identification of the lipopolysaccharide modifications controlled by the Salmonella PmrA/PmrB system mediating resistance to Fe(III) and Al(III) , 2006, Molecular microbiology.

[19]  M. Naguib,et al.  Propofol: The Challenges of Formulation , 2005, Anesthesiology.

[20]  N. Surolia,et al.  Polymyxin B: an ode to an old antidote for endotoxic shock. , 2005, Molecular bioSystems.

[21]  P. Marik,et al.  Propofol: therapeutic indications and side-effects. , 2004, Current pharmaceutical design.

[22]  K. Yamaguchi,et al.  Propofol Improves Skin Flap Survival in a Rat Model: Correlating Reduction in Flap-Induced Neutrophil Activity , 2004, Annals of plastic surgery.

[23]  Ronald N. Jones,et al.  Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control Guidelines , 2001, Journal of Clinical Microbiology.

[24]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[25]  R. Hancock,et al.  Cationic peptides: a new source of antibiotics. , 1998, Trends in biotechnology.

[26]  R. Hancock,et al.  Antiendotoxin activity of cationic peptide antimicrobial agents , 1996, Infection and immunity.

[27]  G. P. Martin,et al.  Bile Salt‐ and Lysophosphatidylcholine‐induced Membrane Damage in Human Erythrocytes , 1992, The Journal of pharmacy and pharmacology.

[28]  E. Gepts,et al.  Pharmacokinetic Implications for the Clinical Use of Propofol , 1989, Clinical pharmacokinetics.

[29]  大溝 裕史.  Mechanism of injection pain with long and long-medium chain triglyceride emulsive propofol , 2007 .

[30]  J. Turnidge,et al.  Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. , 2005, International journal of antimicrobial agents.

[31]  R. Hancock.  Antibacterial peptides and the outer membranes of gram-negative bacilli. , 1997, Journal of medical microbiology.